{
    "nctId": "NCT06367335",
    "briefTitle": "Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer",
    "officialTitle": "Characteristics and Predictors of Chemotherapy-induced Liver Injury in Advanced Breast Cancer Patients Treated With Cyclin-dependent Kinase Inhibitors CDK4/6",
    "overallStatus": "COMPLETED",
    "conditions": "DILI",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 128,
    "primaryOutcomeMeasure": "Incidence of DILI",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All patients with advanced breast cancer (Stage IV) consecutively evaluated at the Oncology Unit of our institution and who have received at least one dose of cyclin-dependent kinase inhibitors CDK4/6 (palbociclib, ribociclib, abemaciclib) since the European Union (EU) approval date (2016, 2017, 2018) and who have been followed-up for at least three months after the administration of the last dose of drug;\n* Subjects willing to participate at the study data collection and aged at least 18.\n\nExclusion Criteria:\n\n* Subjects with hepatocellular carcinoma (HCC).\n* Subjects with chronic active hepatitis of any cause AND/OR cirrhosis.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}